Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 44 | 2025 | 1003 | 10.040 |
Why?
|
| Exercise | 11 | 2023 | 335 | 2.930 |
Why?
|
| Telemedicine | 3 | 2022 | 213 | 1.710 |
Why?
|
| Rhinitis | 6 | 2025 | 181 | 1.540 |
Why?
|
| Sports | 2 | 2022 | 40 | 1.490 |
Why?
|
| Quality of Life | 10 | 2025 | 1744 | 1.390 |
Why?
|
| Pandemics | 6 | 2022 | 812 | 1.260 |
Why?
|
| Betacoronavirus | 3 | 2020 | 269 | 1.210 |
Why?
|
| Eosinophilia | 2 | 2019 | 86 | 1.120 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 328 | 1.060 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 313 | 1.050 |
Why?
|
| Anti-Asthmatic Agents | 5 | 2025 | 79 | 0.960 |
Why?
|
| Allergy and Immunology | 1 | 2024 | 14 | 0.910 |
Why?
|
| Humans | 67 | 2025 | 92337 | 0.900 |
Why?
|
| Sleep Apnea, Obstructive | 4 | 2020 | 217 | 0.890 |
Why?
|
| Sinusitis | 5 | 2024 | 216 | 0.880 |
Why?
|
| Hypersensitivity | 2 | 2022 | 163 | 0.860 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2024 | 259 | 0.760 |
Why?
|
| Health Equity | 1 | 2024 | 99 | 0.740 |
Why?
|
| Gastroesophageal Reflux | 2 | 2022 | 126 | 0.740 |
Why?
|
| Fitness Trackers | 1 | 2021 | 6 | 0.720 |
Why?
|
| Spirometry | 5 | 2024 | 69 | 0.720 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 2 | 2025 | 25 | 0.710 |
Why?
|
| Disease Management | 1 | 2023 | 340 | 0.700 |
Why?
|
| Social Determinants of Health | 1 | 2022 | 105 | 0.690 |
Why?
|
| Comparative Effectiveness Research | 2 | 2018 | 55 | 0.670 |
Why?
|
| Telemetry | 1 | 2020 | 36 | 0.670 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 7 | 0.670 |
Why?
|
| Wearable Electronic Devices | 1 | 2020 | 31 | 0.660 |
Why?
|
| Physical Fitness | 1 | 2020 | 50 | 0.660 |
Why?
|
| Lysophospholipase | 1 | 2019 | 3 | 0.640 |
Why?
|
| Self-Management | 2 | 2019 | 43 | 0.640 |
Why?
|
| Galectins | 1 | 2019 | 11 | 0.640 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 97 | 0.630 |
Why?
|
| Adult | 29 | 2025 | 27532 | 0.620 |
Why?
|
| Natural Language Processing | 1 | 2019 | 43 | 0.600 |
Why?
|
| Self Care | 2 | 2019 | 169 | 0.600 |
Why?
|
| Glycoproteins | 1 | 2019 | 234 | 0.580 |
Why?
|
| Social Media | 1 | 2019 | 100 | 0.540 |
Why?
|
| Depression | 1 | 2020 | 526 | 0.520 |
Why?
|
| Comorbidity | 5 | 2020 | 987 | 0.520 |
Why?
|
| Lung | 3 | 2022 | 1337 | 0.510 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 276 | 0.510 |
Why?
|
| Child | 13 | 2025 | 7334 | 0.490 |
Why?
|
| Obesity | 2 | 2020 | 1016 | 0.490 |
Why?
|
| Inflammation | 4 | 2019 | 1025 | 0.470 |
Why?
|
| Life Style | 3 | 2021 | 176 | 0.470 |
Why?
|
| Allergens | 5 | 2021 | 189 | 0.450 |
Why?
|
| Research Design | 1 | 2018 | 600 | 0.440 |
Why?
|
| Middle Aged | 20 | 2025 | 27030 | 0.440 |
Why?
|
| Olfaction Disorders | 2 | 2025 | 73 | 0.420 |
Why?
|
| Neutrophils | 2 | 2017 | 323 | 0.420 |
Why?
|
| Aged | 15 | 2025 | 19943 | 0.420 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 1150 | 0.410 |
Why?
|
| Evidence-Based Practice | 3 | 2024 | 49 | 0.410 |
Why?
|
| Glucocorticoids | 1 | 2015 | 367 | 0.400 |
Why?
|
| Air Pollution | 2 | 2024 | 93 | 0.390 |
Why?
|
| Vulnerable Populations | 2 | 2023 | 84 | 0.380 |
Why?
|
| Rhinitis, Allergic | 2 | 2022 | 45 | 0.370 |
Why?
|
| United States | 13 | 2025 | 7348 | 0.350 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2025 | 278 | 0.330 |
Why?
|
| Emergency Service, Hospital | 4 | 2022 | 559 | 0.320 |
Why?
|
| Age Factors | 5 | 2024 | 1905 | 0.320 |
Why?
|
| Respiratory System | 1 | 2010 | 119 | 0.320 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 435 | 0.320 |
Why?
|
| Female | 24 | 2025 | 47893 | 0.310 |
Why?
|
| Young Adult | 8 | 2021 | 6624 | 0.300 |
Why?
|
| Sputum | 2 | 2019 | 35 | 0.290 |
Why?
|
| Public Health | 2 | 2020 | 145 | 0.290 |
Why?
|
| Feasibility Studies | 2 | 2021 | 800 | 0.290 |
Why?
|
| Adolescent | 7 | 2023 | 9504 | 0.290 |
Why?
|
| Desensitization, Immunologic | 2 | 2019 | 43 | 0.280 |
Why?
|
| Male | 22 | 2025 | 43925 | 0.280 |
Why?
|
| Smell | 2 | 2025 | 115 | 0.270 |
Why?
|
| Nasal Polyps | 2 | 2024 | 63 | 0.270 |
Why?
|
| Cross-Sectional Studies | 5 | 2025 | 1774 | 0.270 |
Why?
|
| Ecological Momentary Assessment | 2 | 2024 | 33 | 0.270 |
Why?
|
| Weight Loss | 2 | 2020 | 239 | 0.270 |
Why?
|
| Neoplasms | 1 | 2022 | 3117 | 0.260 |
Why?
|
| Chronic Disease | 4 | 2024 | 963 | 0.260 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2023 | 270 | 0.250 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 2729 | 0.250 |
Why?
|
| Nasal Surgical Procedures | 1 | 2025 | 9 | 0.240 |
Why?
|
| Formoterol Fumarate | 1 | 2025 | 10 | 0.240 |
Why?
|
| Lysophospholipids | 2 | 2016 | 66 | 0.230 |
Why?
|
| Menopause | 1 | 2025 | 85 | 0.230 |
Why?
|
| Environmental Exposure | 2 | 2024 | 340 | 0.220 |
Why?
|
| Air Pollution, Indoor | 1 | 2024 | 65 | 0.220 |
Why?
|
| Information Dissemination | 1 | 2024 | 119 | 0.210 |
Why?
|
| Food Supply | 1 | 2023 | 29 | 0.210 |
Why?
|
| Climate Change | 1 | 2023 | 53 | 0.200 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2022 | 20 | 0.200 |
Why?
|
| Exhalation | 1 | 2022 | 7 | 0.200 |
Why?
|
| Breath Tests | 1 | 2022 | 58 | 0.190 |
Why?
|
| Policy | 1 | 2022 | 39 | 0.190 |
Why?
|
| Prevalence | 3 | 2023 | 1294 | 0.190 |
Why?
|
| Life Change Events | 1 | 2022 | 48 | 0.190 |
Why?
|
| Anxiety | 2 | 2022 | 324 | 0.190 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 1919 | 0.190 |
Why?
|
| Masks | 1 | 2021 | 30 | 0.180 |
Why?
|
| Alcohol Drinking | 1 | 2024 | 278 | 0.180 |
Why?
|
| Disinfectants | 1 | 2020 | 8 | 0.180 |
Why?
|
| Environmental Pollutants | 1 | 2021 | 54 | 0.180 |
Why?
|
| Forced Expiratory Volume | 2 | 2022 | 127 | 0.180 |
Why?
|
| Self Report | 2 | 2019 | 307 | 0.180 |
Why?
|
| Nitric Oxide | 1 | 2022 | 283 | 0.170 |
Why?
|
| Counseling | 1 | 2022 | 171 | 0.170 |
Why?
|
| Patient Outcome Assessment | 2 | 2017 | 85 | 0.170 |
Why?
|
| Data Collection | 1 | 2021 | 379 | 0.160 |
Why?
|
| Lung Diseases | 1 | 2022 | 282 | 0.160 |
Why?
|
| Phenotype | 3 | 2017 | 2498 | 0.160 |
Why?
|
| Observer Variation | 2 | 2018 | 612 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 444 | 0.160 |
Why?
|
| Polypharmacy | 1 | 2019 | 19 | 0.150 |
Why?
|
| Respiratory Sounds | 1 | 2018 | 34 | 0.150 |
Why?
|
| Airway Remodeling | 2 | 2016 | 10 | 0.150 |
Why?
|
| Mexican Americans | 1 | 2018 | 68 | 0.150 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 370 | 0.150 |
Why?
|
| Cough | 1 | 2018 | 56 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2023 | 404 | 0.150 |
Why?
|
| Health Promotion | 1 | 2020 | 168 | 0.150 |
Why?
|
| Eosinophils | 1 | 2019 | 197 | 0.150 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2016 | 130 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 373 | 0.150 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2018 | 52 | 0.150 |
Why?
|
| Health Behavior | 1 | 2019 | 185 | 0.140 |
Why?
|
| Phosphoric Diester Hydrolases | 2 | 2016 | 25 | 0.140 |
Why?
|
| Residence Characteristics | 1 | 2018 | 204 | 0.130 |
Why?
|
| Income | 1 | 2017 | 87 | 0.130 |
Why?
|
| Rifampin | 1 | 2016 | 23 | 0.130 |
Why?
|
| Drug Hypersensitivity | 1 | 2016 | 38 | 0.130 |
Why?
|
| Leukocyte Count | 1 | 2017 | 225 | 0.130 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 6916 | 0.130 |
Why?
|
| Anaphylaxis | 1 | 2016 | 33 | 0.130 |
Why?
|
| Immunoglobulin E | 1 | 2017 | 148 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2019 | 900 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 175 | 0.130 |
Why?
|
| Circadian Rhythm | 1 | 2018 | 309 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2020 | 425 | 0.120 |
Why?
|
| Patient Transfer | 1 | 2016 | 103 | 0.120 |
Why?
|
| Complementary Therapies | 1 | 2016 | 55 | 0.120 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 48 | 0.120 |
Why?
|
| Tuberculosis | 1 | 2016 | 124 | 0.120 |
Why?
|
| Biomarkers | 2 | 2019 | 1850 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 446 | 0.120 |
Why?
|
| Odds Ratio | 3 | 2025 | 694 | 0.120 |
Why?
|
| Macrophages, Alveolar | 1 | 2015 | 62 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2794 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1902 | 0.110 |
Why?
|
| Registries | 1 | 2019 | 902 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2018 | 909 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 205 | 0.110 |
Why?
|
| Disease Progression | 1 | 2019 | 1503 | 0.110 |
Why?
|
| Sleep | 1 | 2018 | 461 | 0.110 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2016 | 202 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2017 | 364 | 0.110 |
Why?
|
| Patient Selection | 1 | 2017 | 689 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 1247 | 0.100 |
Why?
|
| Risk Factors | 6 | 2020 | 5704 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2025 | 8740 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1079 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 810 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 2394 | 0.080 |
Why?
|
| Chicago | 3 | 2018 | 1466 | 0.080 |
Why?
|
| Animals | 5 | 2020 | 28003 | 0.070 |
Why?
|
| Aging | 1 | 2013 | 738 | 0.070 |
Why?
|
| Hospitalization | 1 | 2014 | 927 | 0.070 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 611 | 0.070 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2025 | 74 | 0.060 |
Why?
|
| Administration, Inhalation | 1 | 2025 | 193 | 0.060 |
Why?
|
| Environmental Monitoring | 1 | 2024 | 82 | 0.060 |
Why?
|
| Housing | 1 | 2023 | 47 | 0.050 |
Why?
|
| Mobile Applications | 1 | 2024 | 76 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2022 | 9703 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2025 | 807 | 0.050 |
Why?
|
| Demography | 1 | 2022 | 186 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2022 | 104 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2022 | 145 | 0.050 |
Why?
|
| Sex Factors | 1 | 2024 | 1095 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 887 | 0.040 |
Why?
|
| Satellite Imagery | 1 | 2018 | 5 | 0.040 |
Why?
|
| Information Systems | 1 | 2018 | 30 | 0.040 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2018 | 26 | 0.040 |
Why?
|
| Actigraphy | 1 | 2018 | 60 | 0.040 |
Why?
|
| Plants | 1 | 2018 | 118 | 0.040 |
Why?
|
| Health Information Exchange | 1 | 2017 | 12 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 2448 | 0.030 |
Why?
|
| Urban Population | 1 | 2018 | 229 | 0.030 |
Why?
|
| Heart | 1 | 2020 | 584 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 180 | 0.030 |
Why?
|
| Phospholipases A1 | 1 | 2016 | 1 | 0.030 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2016 | 14 | 0.030 |
Why?
|
| Lysophosphatidylcholines | 1 | 2016 | 17 | 0.030 |
Why?
|
| Antigens, Dermatophagoides | 1 | 2015 | 11 | 0.030 |
Why?
|
| Pyroglyphidae | 1 | 2015 | 15 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 673 | 0.030 |
Why?
|
| Chemotaxis | 1 | 2015 | 74 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2015 | 351 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 3110 | 0.030 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2014 | 26 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2022 | 4468 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1661 | 0.030 |
Why?
|
| Population Groups | 1 | 2014 | 41 | 0.030 |
Why?
|
| Caregivers | 1 | 2015 | 177 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2016 | 362 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 1756 | 0.030 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2013 | 52 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2017 | 473 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3775 | 0.020 |
Why?
|
| Cell Line | 1 | 2015 | 2505 | 0.020 |
Why?
|
| Mice | 2 | 2016 | 12110 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 2369 | 0.020 |
Why?
|
| Transcriptome | 1 | 2015 | 699 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2017 | 3818 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 1589 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 5430 | 0.020 |
Why?
|
| Physicians | 1 | 2015 | 694 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 3360 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 3508 | 0.010 |
Why?
|